Tower Research Capital (TRC)’s Zymeworks ZYME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$122K Buy
4,868
+3,515
+260% +$83.2K ﹤0.01% 2034
2025
Q4
$35.6K Sell
1,353
-9,948
-88% -$217K ﹤0.01% 2685
2025
Q3
$193K Buy
11,301
+6,354
+128% +$90.9K 0.01% 1490
2025
Q2
$62.1K Buy
4,947
+1,131
+30% +$13.5K ﹤0.01% 2786
2025
Q1
$45.4K Sell
3,816
-5,888
-61% -$80.3K ﹤0.01% 2289
2024
Q4
$142K Buy
9,704
+7,518
+344% +$105K ﹤0.01% 1937
2024
Q3
$27.4K Sell
2,186
-8,068
-79% -$87.9K ﹤0.01% 3063
2024
Q2
$87.3K Buy
10,254
+6,707
+189% +$59.7K ﹤0.01% 2673
2024
Q1
$37.3K Sell
3,547
-13,545
-79% -$150K ﹤0.01% 2475
2023
Q4
$178K Buy
17,092
+14,612
+589% +$116K ﹤0.01% 2198
2023
Q3
$15.7K Buy
2,480
+643
+35% +$4.75K ﹤0.01% 3600
2023
Q2
$15.9K Sell
1,837
-17,438
-90% -$156K ﹤0.01% 3603
2023
Q1
$174K Buy
19,275
+15,999
+488% +$140K 0.01% 1447
2022
Q4
$26K Buy
+3,276
New +$23K ﹤0.01% 2897
2022
Q3
Sell
-5,184
Closed -$27K 6559
2022
Q2
$27K Buy
5,184
+760
+17% +$4.6K ﹤0.01% 3488
2022
Q1
$29K Sell
4,424
-9,149
-67% -$81.5K ﹤0.01% 3202
2021
Q4
$222K Buy
13,573
+5,742
+73% +$120K ﹤0.01% 1688
2021
Q3
$227K Buy
7,831
+7,695
+5,658% +$256K 0.01% 1702
2021
Q2
$5K Sell
136
-7,865
-98% -$250K ﹤0.01% 4745
2021
Q1
$253K Buy
+8,001
New +$325K ﹤0.01% 1805
2020
Q3
Sell
-542
Closed -$20K 5148
2020
Q2
$20K Buy
+542
New +$20K ﹤0.01% 3691
2019
Q4
Sell
-586
Closed -$15K 4492
2019
Q3
$15K Buy
+586
New +$14.7K ﹤0.01% 2688
2018
Q4
Sell
-293
Closed -$5K 4447
2018
Q3
$5K Sell
293
-927
-76% -$13.3K ﹤0.01% 3145
2018
Q2
$18K Buy
1,220
+908
+291% +$14.1K ﹤0.01% 2503
2018
Q1
$4K Sell
312
-1,454
-82% -$15.7K ﹤0.01% 2813
2017
Q4
$14K Buy
1,766
+1,566
+783% +$12.9K ﹤0.01% 2343
2017
Q3
$2K Sell
200
-200
-50% -$1.55K ﹤0.01% 3602
2017
Q2
$3K Buy
+400
New +$4.48K ﹤0.01% 2253

Other funds holding ZYME

Tower Research Capital (TRC)'s ZYME Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Zymeworks (ZYME) stake by 260% in Q1 2026, buying an estimated $83.2K and bringing the position to 4,868 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #2034.

Tower Research Capital (TRC) first reported a position in ZYME in Q2 2017 and has held it in 28 quarters since. The position peaked at $253K in Q1 2021. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

  • Tower Research Capital (TRC) held 4,868 shares of Zymeworks worth $122K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,515 Zymeworks shares in Q1 2026, an estimated $83.2K.
  • Zymeworks made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2034 holding.
  • Tower Research Capital (TRC) first reported a position in Zymeworks in Q2 2017 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s Zymeworks position peaked at $253K in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.